

Highly Enantioselective Synthesis of Dihydroquinazolinones Catalyzed by SPINOL-Phosphoric Acids


Dan Huang, Xuejian Li, Fangxi Xu, Luhang Li, and Xufeng Lin*

Department of Chemistry, Zhejiang University, Hangzhou 310027, People's Republic of China

S Supporting Information

ABSTRACT: The asymmetric condensation/amine addition cascade sequence of 2-aminobenzamides and aldehydes catalyzed by chiral spirocyclic SPINOL-phosphoric acids was realized. SPINOL-phosphoric acid **1j** was found to be a general, highly enantioselective organocatalyst for such cascade reactions at room temperature, affording 2,3-dihydroquinazolinones in excellent yields (up to 99%) with good to excellent ee's (up to 98%). The best level of stereocontrol was obtained for aromatic aldehydes with an ortho substituent.

KEYWORDS: phosphoric acid, asymmetric, 2-aminobenzamide, dihydroquinazolinone, organocatalysis



The 2,3-dihydroquinazolinone family of compounds displays extensive important pharmacological activities, such as antitumor, analgesic, antifibrillatory, antibiotic, antispermato-genic, and vasodilatory efficacy.¹ In addition, it has been reported that their enantiomers have different bioactivities.^{1a,2} Consequently, the development of new methodologies for asymmetric synthesis of 2,3-dihydroquinazolinones has been an intense focus. In this context, a few methods have been documented.³ The first success in the field was reported by List et al. who applied chiral BINOL-phosphoric acids^{4,5} as the catalysts in the asymmetric synthesis of 2,3-dihydroquinazolinones (limited to aliphatic aldehydes, 72–94% yields, and 50–98% ee's, –45 °C).^{3a} Simultaneously, Rueping et al. also reported the corresponding enantioselective synthesis using the same class of phosphoric acids (limited to aromatic aldehydes without an ortho substituent, 73–93% yields, and 80–92% ee's).^{3b} Tian et al. recently developed a new method for the BINOL-phosphoric acid-catalyzed asymmetric synthesis of 2,3-dihydroquinazolinones from imines and 2-aminobenzamides with substrate diversity (limited to the use of preformed imines, 54–90% yields, and 83–97% ee's, –20 °C).^{3c} More recently, Kesavan et al. described the first Sc(III)-inda-pybox-catalyzed enantioselective version (limited to aromatic aldehydes without an ortho substituent and aliphatic aldehydes, 80–97% yields, and 80–98% ee's, –20 °C to rt).^{3d} Despite these elegant examples, a general, efficient, and mild enantioselective protocol has yet to be described and would be of a great value because of the importance of optically active 2,3-dihydroquinazolinones.

Our group has great interest in the development of chiral 1,1'-spirobiindane-7,7'-diol (SPINOL)-based spirocyclic phosphoric acids **1** (Figure 1) and derivatives as novel organo-catalysts for asymmetric reactions and has showed their excellent catalytic reactivity as chiral Brønsted acid catalysts.^{6–8}

These previous successes led us to envision that SPINOL-phosphoric acids might be highly enantioselective catalysts for the asymmetric condensation/amine addition cascade sequence





Figure 1. Chiral SPINOL-phosphoric acids.

Table 1. Catalyst Investigation^a




entry	catalyst	yield ^b (%)	ee ^c (%)
1	1a	96	72
2	1b	99	73
3	1c	97	70
4	1d	96	70
5	1e	98	66
6	1f	97	23
7	1g	96	82
8	1h	98	74
9	1i	98	59
10	1j	98	88

^aReaction conditions: catalyst **1** (10 mol %), **2a** (0.05 mmol), **3a** (0.055 mmol), CHCl₃ (1.0 mL), molecular sieves (3 Å, 75 mg), rt, 24 h. ^bIsolated yields. ^cDetermined by chiral HPLC.

Received: July 22, 2013

Revised: September 3, 2013

Published: September 6, 2013

Table 2. Optimization of the Reaction Conditions^a




entry	solvent	yield ^b (%)	ee ^c (%)
1	THF	77	11
2	toluene	88	43
3	ClCH ₂ CH ₂ Cl	89	58
4	CH ₂ Cl ₂	98	58
5	CCl ₄	60	61
6	CHCl ₃	98	88
7 ^d	CHCl ₃	97	69
8 ^e	CHCl ₃	79	73
9 ^f	CHCl ₃	97 (95)	88 (88)

^aGeneral conditions: catalyst **1j** (10 mol %), **2a** (0.05 mmol), **3a** (0.055 mmol), solvent (1.0 mL), 3 Å MS (powdered, 75 mg), rt, 24 h. ^bIsolated yields. ^cDetermined by chiral HPLC. ^dAmberlite CG50 (50 mg) was added. ^e48 h at 0 °C. ^f1.0 mmol scale experiment, data in parentheses were obtained using the recovered catalyst **1j**.

of 2-aminobenzamides and aldehydes. Herein, we present our preliminary results on this subject.

The initial studies were carried out using the reaction of 2-aminobenzamide (**2a**) and 4-bromobenzaldehyde (**3a**) as the model substrates with 10 mol % of catalyst in chloroform at room temperature in the presence of powdered 3 Å molecular sieves. We first investigated the influence of catalyst. A series of chiral SPINOL-phosphoric acids (*S*)-**1a–j** were screened, as shown in Table 1. Indeed, the reaction proceeded to afford the desired optically active 2,3-dihydroquinazolinone **4a** in excellent yields using catalyst (*S*)-**1**. The screening of SPINOL-phosphoric acids (*S*)-**1a–j** showed that the 6,6'-substituents on the SPINOL backbone remarkably affected the enantioselectivity. The catalyst (*S*)-**1j** (Ar = 9-anthracenyl) revealed the highest enantioselectivity at room temperature to afford 2,3-dihydroquinazolinone **4a** in 98% yield with 88% ee (entry 10, Table 1).

Then, the reaction was studied under different reaction conditions, and the results are summarized in Table 2. A solvent screen revealed that chloroform gave the corresponding product **4a** in both the highest yield and enantioselectivity (entries 1–6, Table 2), although other solvents, such as THF, toluene, ClCH₂CH₂Cl, CH₂Cl₂, and CCl₄, also gave the desired product with good to excellent yields but poor enantioselectivity (entries 1–5, Table 2). The reaction with Amberlite CG50 as an additive led to remarkably lowered enantioselectivity (97% yield, 69% ee, entry 7, Table 2). Lowering the temperature to 0 °C remarkably lowered the yield and enantioselectivity (79% yield, 73% ee, entry 8, Table 2). Thus, the optimized reaction conditions for the model reaction were established (entry 6, Table 2). Furthermore, the scalability of the newly investigated method was proven with a 1.0 mmol scale experiment (entry 9, Table 2). The 2,3-dihydroquinazolinone **4a** was achieved in 97% yield and 88% ee at room temperature. To illustrate the recycling of the catalyst (*S*)-**1j**, the recovered catalyst in the above reaction was then reused directly in the next reaction with a 1.0 mmol scale experiment, and the same procedure was repeated to exhibit the compared catalytic activity and enantioselectivity (95% yield, 88% ee, entry 9, Table 2).

Table 3. Substrate Scope^{a,b,c}

^aReaction conditions: catalyst **1j** (10 mol %), **2** (0.05 mmol), **3** (0.055 mmol), CHCl₃ (1.0 mL), 3 Å MS (powdered, 75 mg), rt, 24 h. ^bIsolated yields. ^cDetermined by chiral HPLC.




Figure 2. Possible transition state of the reaction.

With these reaction conditions identified, our attention turned to examination of the scope of catalytic asymmetric condensation/amine addition cascade reaction. The reactions were carried out using catalyst **1j** under the optimized conditions, and the results are summarized in Table 3. All reactions proceeded in generally excellent yields with good to excellent enantioselectivities. The influence of the aldehyde substrates was first investigated. Either electron-withdrawing or -donating substituents (-Br, -NO₂, -Cl, -OMe, -OCH₂O-) on the phenyl group of aromatic aldehydes could be well tolerated, affording their desired products **4a–l**. It is noteworthy that a different position-substituent on the phenyl group of aromatic aldehydes appears to have a remarkable effect on the enantioselectivity. We found that the best level of stereocontrol was obtained for aromatic aldehydes with an ortho substituent, such as **4b** (98% ee), **4d** (95% ee), **4f** (98% ee), **4g** (96% ee), and **4i** (94% ee). The 1-naphthyl-bearing substrate also led to product **4m** in 99% yield and 97% ee, whereas a 2-naphthyl-bearing substrate gave product **4n** in only 89% yield and 89% ee. When a cyclohexyl substituent was introduced, the reaction ran smoothly, affording the product **4o** in 98% yield and 84% ee. We further expanded the scope of this cascade reaction to substituted 2-aminobenzamide. Reaction of 1-naphthaldehyde and *ortho*-chlorobenzaldehyde with 5-iodo-2-aminobenzamide, which can participate in subsequent transformations, such as cross-coupling reactions, gave the corresponding 2,3-dihydroquinazolinone **4p** and **4q** in good yields with excellent ee's.

The absolute stereochemistry of product **4c**, obtained by using the catalyst (*S*)-**1j**, was determined to be *S* by comparison of its optical rotation with the literature data.^{3b} Thus, a possible transition state of this reaction is proposed in Figure 2. It is clear that the enantioselectivity is determined by the step of intramolecular amidation of imine. SPINOL-phosphoric acid (*S*)-**1j** as a bifunctional organocatalyst brings together two groups (amine and imine) through hydrogen bonding. In this model, the amine attacks the imine from the *Si* face preferentially as a result of less steric hindrance, resulting in the *S* stereoisomer.

In summary, we have developed an efficient and practical protocol to synthesize optically active 2,3-dihydroquinazolinones by chiral SPINOL-phosphoric acid-catalyzed asymmetric condensation/amine addition cascade sequence of 2-aminobenzamides and aldehydes. Following this methodology, a series of 2,3-dihydroquinazolinones were obtained in excellent yields (up to 99%) with good to excellent ee's (up to 98%) at room temperature. In addition, we found that a different position-substituent on the phenyl group of aromatic aldehydes appears to have a remarkable effect on the enantioselectivity. The best level of stereocontrol was obtained for aromatic aldehydes with an ortho substituent. Furthermore, the scalability of the newly investigated method was proven with a 1.0-mmol scale experiment, and the recycling of the catalyst was illustrated.

■ ASSOCIATED CONTENT

Supporting Information

Experimental procedures and characterization of the products. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: lxfolk@zju.edu.cn.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We thank the National Natural Foundation of China (21272202 and J1210042) and the Fundamental Research Funds for the Central Universities for financial support.

■ REFERENCES

- (1) (a) Chinigo, G. M.; Paige, M.; Grindrod, S.; Hamel, E.; Dakshanamurthy, S.; Chruszcz, M.; Minor, W.; Brown, M. L. *J. Med. Chem.* **2008**, *51*, 4620. (b) Okumura, K.; Oine, T.; Yamada, Y.; Hayashi, G.; Nakama, M. *J. Med. Chem.* **1968**, *11*, 348. (c) Bonola, G.; Da Re, P.; Magistretti, M. J.; Massarani, E.; Setnikar, I. *J. Med. Chem.* **1968**, *11*, 1136. (d) Russel, H. E.; Alaimo, R. J. *J. Med. Chem.* **1972**, *15*, 335. (e) Neil, G. L.; Li, L. H.; Buskirk, H. H.; Moxley, T. E. *Cancer Chemother.* **1972**, *56*, 163. (f) Levin, J. I.; Chan, P. S.; Bailey, T.; Katocs, A. S.; Venkatesan, A. M. *Bioorg. Med. Chem. Lett.* **1994**, *4*, 1141.
- (2) Uzunov, D. P.; Zivkovich, I.; Pirkle, W. H.; Costa, E.; Guidotti, A. *J. Pharm. Sci.* **1995**, *84*, 937.
- (3) (a) Cheng, X.; Vellalath, S.; Goddard, R.; List, B. *J. Am. Chem. Soc.* **2008**, *130*, 15786. (b) Rueping, M.; Antonchick, A. P.; Sugiono, E.; Grenader, K. *Angew. Chem., Int. Ed.* **2009**, *48*, 908. (c) Cheng, D. J.; Tian, Y.; Tian, S. K. *Adv. Synth. Catal.* **2012**, *354*, 995. (d) Prakash, M.; Kesavan, V. *Org. Lett.* **2012**, *14*, 1896.
- (4) For recent reviews of chiral phosphoric acid catalysis, see: (a) Terada, M. *Synthesis* **2010**, 1929. (b) Akiyama, T. *Chem. Rev.* **2007**, *107*, 5744. (c) Kampen, D.; Reisinger, C. M.; List, B. *Top. Curr. Chem.* **2010**, *291*, 395. (d) Rueping, M.; Kuenkel, A.; Atodiresi, I. *Chem. Soc. Rev.* **2011**, *40*, 4539. (e) Terada, M. *Chem. Commun.* **2008**, 4097. (f) Yu, J.; Shi, F.; Gong, L. Z. *Acc. Chem. Res.* **2011**, *44*, 1156. (g) You, S.; Cai, Q.; Zeng, M. *Chem. Soc. Rev.* **2009**, *38*, 2190. (h) Yu, X.; Wang, W. *Chem.-Asian J.* **2008**, *3*, 516.
- (5) For selected examples of the application of chiral phosphoric acid catalysis, see: (a) Akiyama, T.; Itoh, J.; Yokota, K.; Fuchibe, K. *Angew. Chem., Int. Ed.* **2004**, *43*, 1566. (b) Uruguchi, D.; Terada, M. *J. Am. Chem. Soc.* **2004**, *126*, 5356. (c) Rowland, G.; Zhang, H.; Rowland, E.; Chennamadhavuni, S.; Wang, Y.; Antilla, J. C. *J. Am. Chem. Soc.* **2005**, *127*, 15696. (d) Hoffmann, S.; Seayad, A. M.; List, B. *Angew. Chem., Int. Ed.* **2005**, *44*, 7424. (e) Magnus, R.; Sugiono, E.; Azap, C.; Theissmann, T.; Bolte, M. *Org. Lett.* **2005**, *7*, 3781. (f) Storer, R. I.; Carrera, D. E.; Ni, Y.; MacMillan, D. W. C. *J. Am. Chem. Soc.* **2006**, *128*, 84. (g) Liu, H.; Cun, L.-F.; Mi, A.-Q.; Jiang, Y. Z.; Gong, L. Z. *Org. Lett.* **2006**, *8*, 6023. (h) Xu, S.; Wang, Z.; Zhang, X.; Ding, K. *Angew. Chem., Int. Ed.* **2008**, *47*, 2840. (i) Lu, M.; Zhu, D.; Lu, Y.; Zeng, X.; Tan, B.; Xu, Z.; Zhong, G. *J. Am. Chem. Soc.* **2009**, *131*, 4562. (j) Liu, H.; Dagousset, G.; Masson, G.; Retailleau, P.; Zhu, J.-P. *J. Am. Chem. Soc.* **2009**, *131*, 4598.
- (6) (a) Xu, F.; Huang, D.; Han, C.; Shen, W.; Lin, X. F.; Wang, Y. *J. Org. Chem.* **2010**, *75*, 8677. (b) Huang, D.; Xu, F. X.; Lin, X. F.; Wang, Y. *Chem.—Eur. J.* **2012**, *18*, 3148. (c) Xu, F.; Huang, D.; Lin, X. F.; Wang, Y. *Org. Biomol. Chem.* **2012**, *10*, 4467. (d) Huang, D.; Xu, F.; Chen, T.; Wang, Y.; Lin, X. F. *RSC Adv.* **2013**, *3*, 573. (e) Li, X.; Zhao, Y.; Qu, H.; Mao, Z.; Lin, X. F. *Chem. Commun.* **2013**, *49*, 1401. (f) Zhao, Y.; Li, X.; Mo, F.; Li, L.; Lin, X. F. *RSC Adv.* **2013**, *3*, 11895.

(7) For a simultaneous report on the development of chiral SPINOL-phosphoric acid, see: Čorić, I.; Müller, S.; List, B. *J. Am. Chem. Soc.* **2010**, *132*, 17370.

(8) For selected examples of the other application of chiral SPINOL-phosphoric acid catalysis, see: (a) Xing, C.; Liao, Y.; Ng, J.; Hu, Q. *J. Org. Chem.* **2011**, *76*, 4125. (b) Xu, B.; Zhu, S.; Xie, X.; Shen, J.; Zhou, Q. *Angew. Chem., Int. Ed.* **2011**, *50*, 11483. (c) Müller, S.; Webber, M.; List, B. *J. Am. Chem. Soc.* **2011**, *133*, 18534. (d) Xing, C.; Liao, Y.; Zhang, Y.; Sabarova, D.; Assous, B.; Hu, Q. *Eur. J. Org. Chem.* **2012**, 1115. (e) Rubush, D.; Morges, M.; Rose, B.; Thamm, D.; Rovis, T. *J. Am. Chem. Soc.* **2012**, *134*, 13554. (f) Chen, Z.; Wang, B.; Wang, Z.; Zhu, G.; Sun, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 2027. (g) Guin, J.; Varseev, G.; List, B. *J. Am. Chem. Soc.* **2013**, *135*, 2100. (h) Chen, Z.; Wang, B.; Sun, J. *Chem.—Eur. J.* **2013**, *19*, 8426. (i) Wang, B.; Chen, Z.; Sun, J. *Angew. Chem., Int. Ed.* **2013**, *52*, 6685. (j) Martinez, A.; Webber, M. J.; Müller, S.; List, B. *Angew. Chem., Int. Ed.* **2013**, *52*, 9486. (k) Cai, Q.; Liang, X.; Wang, S.; You, S. *Org. Biomol. Chem.* **2013**, *11*, 1602.